173 results on '"Borsche, Max"'
Search Results
2. POLG2-Linked Mitochondrial Disease: Functional Insights from New Mutation Carriers and Review of the Literature
3. Genotype–phenotype correlation in PRKN-associated Parkinson’s disease
4. Bilateral vestibulopathy in RFC1-positive CANVAS is distinctly different compared to FGF14-linked spinocerebellar ataxia 27B
5. Estimates of protection levels against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season: the IMMUNEBRIDGE project
6. Participant perspective on the recall-by-genotype research approach: a mixed-method embedded study with participants of the CHRIS study
7. Characterization of the pathogenic α-Synuclein Variant V15A in Parkinson´s disease
8. Depressive symptoms in Parkinson’s disease are insufficiently but more often treated than in other chronic conditions
9. Nachbefragung zur Qualitätssicherung der ELISA-Kohortenstudie zur COVID-19-Prävalenz: Die Sicht von Studienteilnehmerinnen und Studienteilnehmern – Was kommt gut an?
10. Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study – a prospective population-based cohort study
11. Influence of non-pharmaceutical interventions during the COVID-19 pandemic on respiratory viral infections - a prospective population-based cohort study.
12. α‐Synuclein Pathology in PRKN‐Linked Parkinson's Disease: New Insights from a Blood‐Based Seed Amplification Assay
13. RFC1 and FGF14 Repeat Expansions in Serbian Patients with Cerebellar Ataxia
14. The role of dopaminergic medication, lipid, and endocannabinoid pathway alterations in idiopathic andPRKN/PINK1-mediated Parkinson’s disease – a large-scale targeted metabolomics study
15. Balancing scientific interests and the rights of participants in designing a recall by genotype study
16. Don't do harm by diagnosis - An abnormal cranial CT: Still fa(h)r from a disease
17. Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19
18. Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort
19. Parkinsondiagnose per Blutuntersuchung
20. Estimates of protection levels against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season: the IMMUNEBRIDGE project
21. Immune correlates against SARS-CoV-2 infection – results of population and hospital-based studies in the IMMUNEBRIDGE project in Germany, 2022
22. Blood‐Based α‐Synuclein Seeding—A New Era for Identifying Parkinsonian Syndromes
23. Transition to endemic: Two-year SARS-CoV-2 surveillance follow-up of the ELISA cohort
24. POLG2-Linked Mitochondrial Disease: Functional Insights from New Mutation Carriers and Review of the Literature
25. Sez6l2-antibody-associated progressive cerebellar ataxia: a differential diagnosis of atypical parkinsonism
26. Parkin and PINK1 mitigate STING-induced inflammation
27. Morbus Parkinson
28. The New p. F1700L LRRK2 Variant Causes Parkinson's Disease by Extensively Increasing Kinase Activity
29. Estimates of protection against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season - the IMMUNEBRIDGE project
30. In Vivo Investigation of Glucose Metabolism in Idiopathic and PRKN ‐Related Parkinson's Disease
31. Mitochondrial DNA heteroplasmy distinguishes disease manifestation in PINK1/PRKN-linked Parkinson's disease.
32. Mitochondrial DNA heteroplasmy distinguishes disease manifestation in PINK1/PRKN-linked Parkinson’s disease
33. Mitochondrial DNA heteroplasmy distinguishes disease manifestation in PINK1- and PRKN-linked Parkinson's disease 2022.05.17.22275087
34. Mitochondrial DNA heteroplasmy distinguishes disease manifestation in PINK1- and PRKN-linked Parkinson’s disease
35. Head impulse testing in bilateral vestibulopathy in patients with genetically defined CANVAS
36. One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk
37. Additional file 1 of Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study – a prospective population-based cohort study
38. Task matters - challenging the motor system allows distinguishing unaffected Parkin mutation carriers from mutation-free controls
39. Eosinophils Suppress the Migration of T Cells Into the Brain of Plasmodium berghei-Infected Ifnar1-/- Mice and Protect Them From Experimental Cerebral Malaria
40. Behandlung der Zervikalen Dystonie mit Botulinumtoxin – Schritt für Schritt
41. Frequency of Heterozygous Parkin (PRKN) Variants and Penetrance of Parkinson's Disease Risk Markers in the Population-Based CHRIS Cohort
42. Predictive modeling of spread in adult‐onset isolated dystonia: Key properties and effect of tremor inclusion
43. A Multi‐center Genome‐wide Association Study of Cervical Dystonia
44. The New p.F1700L LRRK2 Variant Causes Parkinson's Disease by Extensively Increasing Kinase Activity.
45. Cohort-based surveillance of SARS-CoV2 transmission mirrors infection rates at the population level: a one-year longitudinal study
46. Mitochondria and Parkinson's Disease: Clinical, Molecular, and Translational Aspects
47. Mitochondria and Parkinson’s Disease: Clinical, Molecular, and Translational Aspects
48. Metabolic markers distinguish COVID-19 from other intensive care patients and show potential to stratify for disease risk
49. Spreading of SARS-CoV-2 Among Adult Asylum Seekers in Refugee Shelters in Germany
50. Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.